Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/19/2018 |
| Start Date: | February 19, 2009 |
| End Date: | January 8, 2015 |
Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy of Patients With 1- 4 Brain Metastases From Solid Malignancies
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause
less damage to normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of bendamustine when
given together with radiation therapy in treating patients with brain metastases caused by
solid tumors.
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause
less damage to normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of bendamustine when
given together with radiation therapy in treating patients with brain metastases caused by
solid tumors.
OBJECTIVES:
Primary
- Determine the recommended phase II dose of bendamustine hydrochloride when administered
in combination with stereotactic radiotherapy for the treatment of patients with 1-4
brain metastases from solid malignancies.
Secondary
- Determine bendamustine hydrochloride pharmacokinetics and correlate this to bendamustine
hydrochloride levels in brain metastases, brain margin, arachnoid, cerebral spinal
fluid, and plasma acquired at the time of surgery.
- Assessment of local control of brain metastases.
OUTLINE: This is a dose-escalation study of bendamustine hydrochloride.
Patients with no potentially resectable lesion(s) receive bendamustine hydrochloride IV over
30 minutes and stereotactic radiotherapy once daily for 5 days.
Patients with potentially resectable lesion(s) receive bendamustine hydrochloride IV over 30
minutes on days 1-3 and undergo surgery on day 3. At least 4 weeks after surgery, these
patients receive adjuvant bendamustine hydrochloride and stereotactic fractionated
radiotherapy as above (in patients with no potentially resectable lesion[s])
Blood samples are collected periodically for pharmacokinetic studies. Cerebrospinal fluid,
arachnoid, tumor margin, and tumor samples are also collected during surgery for correlative
studies.
After completion of study treatment, patients are followed every 3 months for 21 months.
Primary
- Determine the recommended phase II dose of bendamustine hydrochloride when administered
in combination with stereotactic radiotherapy for the treatment of patients with 1-4
brain metastases from solid malignancies.
Secondary
- Determine bendamustine hydrochloride pharmacokinetics and correlate this to bendamustine
hydrochloride levels in brain metastases, brain margin, arachnoid, cerebral spinal
fluid, and plasma acquired at the time of surgery.
- Assessment of local control of brain metastases.
OUTLINE: This is a dose-escalation study of bendamustine hydrochloride.
Patients with no potentially resectable lesion(s) receive bendamustine hydrochloride IV over
30 minutes and stereotactic radiotherapy once daily for 5 days.
Patients with potentially resectable lesion(s) receive bendamustine hydrochloride IV over 30
minutes on days 1-3 and undergo surgery on day 3. At least 4 weeks after surgery, these
patients receive adjuvant bendamustine hydrochloride and stereotactic fractionated
radiotherapy as above (in patients with no potentially resectable lesion[s])
Blood samples are collected periodically for pharmacokinetic studies. Cerebrospinal fluid,
arachnoid, tumor margin, and tumor samples are also collected during surgery for correlative
studies.
After completion of study treatment, patients are followed every 3 months for 21 months.
Inclusion Criteria:
- Histologically confirmed cancer with 1 to 4 brain metastases imaged by MRI/CT scans
not involving thalamus, basal ganglia or brain stem.
- No cancer originating in central nervous system
- Candidate for clinically indicated surgery to resect brain lesions.
- Karnofsky score of at least 60
- At least 18 years of age
- Life expectancy of more than two months
Exclusion Criteria:
- Evidence of leptomeningeal metastases.
- Need immediate treatment to prevent neurological deterioration.
- Prior brain radiotherapy or surgery for current brain metastases.
- Radiosensitive primary tumors such as small cell lung cancer, germ cell tumors,
lymphoma, leukemia or multiple myeloma.
- Absolute neutrophil count (ANC)<1500/mm3 or platelets <50,000/mms.
- Brain metastasis diameter greater than 5 cm.
- Not pregnant or nursing
- More than 3 weeks since prior chemotherapy.
- No evidence of ischemia on EKG and/or reduced cardiac ejection fraction (i.e., < 50%)
on ECHO.
- No known sensitivity or allergy to bendamustine hydrochloride or mannitol
- No more than 3 prior cytotoxic chemotherapy regimens
- No unresolved persistent toxicities for 4 weeks from prior chemotherapy or 6 weeks for
nitrosoureas.
- Calculated creatinine clearance <40 ml/min.
We found this trial at
1
site
Click here to add this to my saved trials
